
Revenio Investor Relations Material
Latest events

Q1 2025
Revenio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Revenio Group
Access all reports
Revenio Group Oyj designs, manufactures, and sells medical instruments for the early detection of glaucoma, diabetic retinopathy, and macular degeneration. The company's vision is to create a world without blindness. It offers ophthalmology and optometry products like the Topcon Refractometer, the Diagnolyzer FT, the Diabetoscan DR/A1C+, and the XDM-400 Cell Health Analyzer; cell health analysis systems for measuring cellular health of skin cells, bone marrow cells and dental pulp cells; as well as other medical devices that measure the mechanical stress of tissues by stethoscopy (examination of tissues via a stethoscope) and laser Doppler flowmetry (measures blood flow in tissue), and enables quantitative analysis of renal function. The company is based in Vantaa, Finland.
Key slides for Revenio Group


Q4 2024
Revenio Group


Q1 2025
Revenio Group
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
REG1V
Country
🇫🇮 Finland